KPV
Anti-Inflammatory Tripeptide | Alpha-MSH Fragment
Overview
KPV is a potent anti-inflammatory tripeptide derived from the C-terminal of alpha-MSH. It exhibits remarkable anti-inflammatory and antimicrobial properties without the pigmentation effects of full α-MSH, making it ideal for inflammation management.
Key benefits
- Systemic anti-inflammatory effects
- No pigmentation/tanning effects
- Immune modulation without immunosuppression
- Potential for autoimmune conditions
- Gut health support
- Multiple delivery routes available
Mechanism of action
Enters cells and inhibits inflammatory pathways at the nuclear level, particularly NF-κB signaling. Reduces pro-inflammatory cytokines (TNF-α, IL-6) without causing immunosuppression like steroids.
Molecular data
- Type
- Tripeptide
- Half-life
- 1-2 hours
Indications
What the research community uses this compound for, with self-reported effectiveness.
Inflammation
Systemic Inflammation
Most effectiveReduces TNF-α and IL-6 through NF-κB pathway inhibition.
Autoimmune Modulation
EffectiveMay help balance overactive immune responses in autoimmune conditions.
Joint Inflammation
EffectivePotential benefits for inflammatory arthritis through cytokine reduction.
Gut Health
IBD Support
EffectiveDemonstrated benefit in Crohn's disease and ulcerative colitis models.
Intestinal Barrier Repair
EffectiveHelps restore intestinal barrier function.
Microbiome Balance
ModerateSelective antimicrobial activity preserves beneficial gut bacteria.
Skin Health
Psoriasis/Dermatitis
EffectiveTopical KPV reduced psoriatic markers by 60% and improved skin barrier function.
Skin Inflammation
EffectiveReduces inflammatory skin conditions without systemic effects.
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Injectable
Subcutaneous injection provides systemic anti-inflammatory effects. Abdomen is preferred for gut-related issues.
| Protocol | Dose | Frequency | Route / duration |
|---|---|---|---|
| General anti-inflammatory | 200-300mcg | Once daily | SubQ |
| Active inflammation | 250mcg | Twice daily | SubQ |
| Autoimmune support | 500mcg | Once daily | SubQ |
| Acute flare-ups | 500mcg | 2x daily for 1 week, then reduce | SubQ |
Preparation
You will need
- KPV lyophilized powder
- Bacteriostatic water
- Insulin syringes
- Alcohol swabs
Steps
- Clean vial with alcohol pad
- Add 1mL bacteriostatic water to 1mg vial (1000mcg/mL)
- Or add 2mL for 500mcg/mL concentration
- Gently swirl - dissolves easily
- Solution should be clear and colorless
- Label with concentration and date
- Refrigerate immediately
Work out the water volume and syringe units in the reconstitution calculator →
Oral
Oral administration provides direct gut exposure for intestinal conditions.
| Protocol | Dose | Frequency | Route / duration |
|---|---|---|---|
| Gut health support | 200-500mcg | 2-3x daily | Mix in water/juice or enteric capsules |
Topical
Topical cream/gel for localized skin inflammation without systemic absorption.
| Protocol | Dose | Frequency | Route / duration |
|---|---|---|---|
| Skin inflammation | 0.1-0.5% cream/gel | 2-3x daily | Affected skin areas |
Nasal
Nasal spray with limited data. May provide systemic effects through nasal absorption.
| Protocol | Dose | Frequency | Route / duration |
|---|---|---|---|
| Systemic anti-inflammatory | 100-300mcg | 2-3x daily (1-2 sprays per nostril) | Nasal spray |
Interactions
Pairwise interactions with other compounds you might be cycling — the same data behind the cycle builder's safety check.
Melanotan II
MonitorBoth are α-MSH related; KPV lacks pigmentation effects but monitor for cumulative effects.
BPC-157
SynergisticEnhanced gut healing and anti-inflammatory effects through complementary mechanisms.
TB-500
CompatibleDifferent mechanisms; can be combined safely.
LL-37
SynergisticComplementary antimicrobial and healing effects.
Thymosin Alpha-1
CompatibleBoth support immune function through different pathways.
GHK-Cu
SynergisticSynergistic for skin health and regeneration.
Timeline
Typical week-by-week effects reported in clinical and observational data.
- Days 1-3
Subtle reduction in inflammation, improved energy
- Week 1
Noticeable decrease in inflammatory symptoms
- Week 2-3
Improved gut function (if applicable), reduced pain/swelling
- Week 4
Significant improvement in inflammatory markers
- Week 6-8
Sustained benefits, improved quality of life
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Minimal to no side effects reported
- Does not cause immunosuppression like steroids
- No melanin production/tanning effects
- May temporarily reduce inflammation-related symptoms
Stop signs — stop and seek advice
- Signs of infection (fever, chills) - very rare
- Severe injection site reactions
- Paradoxical inflammation increase
- Allergic reaction symptoms
- Unusual fatigue or weakness
Contraindications
- Known peptide allergies
- Active severe infections (theoretical)
- Pregnancy or breastfeeding (limited data)
Monitoring
- Monitor for signs of infection (rare)
- Track inflammatory symptom improvement
- Generally well-tolerated at higher doses
Quality checks
What a legitimate product looks like, what should give pause, and what should make you stop.
Good signs
- High purity >98%
- Clear, colorless solution after reconstitution
- Stable small peptide structure
- Certificate of analysis available
Warning signs
- pH should be 5.5-7 for optimal stability
Stop signs — don't use
- Visible particles indicate contamination/degradation
- Yellow coloration indicates oxidation/potency loss
Recent research
Newer papers and trial readouts on file for this compound, with source and date.
December 2024 · Advanced Healthcare Materials
KPV and Rapamycin Self-Assembled Nanodrug for Vascular Calcification
KPV and rapamycin self-assembled into carrier-free nanoparticles that significantly inhibited vascular calcification in mice by suppressing inflammation and activating autophagy.
September 2024 · International Journal of Pharmaceutics
PepT1-Targeted Nanodrug for Combined Treatment of DSS-Induced Colitis
Novel PepT1-targeted nanodrug combining anti-inflammatory KPV peptide and immunosuppressant for combined treatment of acute and chronic colitis models.
2025 · Drug Delivery and Translational Research
Peptide-Based Therapeutic and Delivery Strategies for IBD: Challenges and Future Directions
Comprehensive review covering KPV among advanced peptide-based therapeutics and delivery strategies for inflammatory bowel disease treatment.
References
Primary literature and clinical-trial data informing this entry.
Dissection of the Anti-Inflammatory Effect of the Core and C-Terminal (KPV) Alpha-Melanocyte-Stimulating Hormone Peptides
Getting, S.J., Schiöth, H.B., Perretti, M. · Journal of Pharmacology and Experimental Therapeutics · 2003
Established that KPV exerts anti-inflammatory effects distinct from core MSH peptides, likely through inhibition of IL-1β functions rather than melanocortin receptor signaling.
PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation
Dalmasso, G., et al. · Gastroenterology · 2008
KPV is transported into cells via PepT1, where nanomolar concentrations inhibit NF-κB and MAP kinase signaling pathways. Oral KPV reduced DSS- and TNBS-induced colitis in mice.
Melanocortin-Derived Tripeptide KPV Has Anti-Inflammatory Potential in Murine Models of Inflammatory Bowel Disease
Kannengiesser, K., et al. · Inflammatory Bowel Diseases · 2008
KPV showed significant anti-inflammatory effects in DSS colitis and CD45RBhi transfer colitis models, reducing weight loss, histological damage, and MPO activity. Effects partially independent of MC1R signaling.
Critical Role of PepT1 in Promoting Colitis-Associated Cancer and Therapeutic Benefits of KPV
Viennois, E., et al. · Cellular and Molecular Gastroenterology and Hepatology · 2016
PepT1 is highly expressed in human colorectal tumors. PepT1-transported KPV prevented colitis-associated carcinogenesis in wild-type mice, with no effect in PepT1-knockout mice, confirming PepT1-dependent therapeutic mechanism.
Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis
Xiao, B., et al. · Molecular Therapy · 2017
HA-functionalized KPV nanoparticles (~272.3 nm) successfully targeted colonic epithelial cells and macrophages, exerting combined mucosal healing and anti-inflammatory effects superior to free KPV in a UC mouse model.
Last updated . How this page was sourced is described in the methodology.